23andMe Holding is engaged in developing direct-to-consumer precision medicine platform and a portfolio of genetically validated therapeutic candidates for various diseases across different therapeutic areas. Co.'s segments are: Consumer and Research Services, which provides its Personal Genome Service® telehealth business and research services; and Therapeutics, which focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies and consists of out-licensing of intellectual property associated with identified drug targets and activities related to therapeutic product candidates. The ME average annual return since 2021 is shown above.
The Average Annual Return on the ME average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ME average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|